Travere Therapeutics Statistics
Share Statistics
Travere Therapeutics has 88.8M
shares outstanding. The number of shares has increased by 16.57%
in one year.
| Shares Outstanding | 88.8M |
| Shares Change (YoY) | 16.57% |
| Shares Change (QoQ) | 1.96% |
| Owned by Institutions (%) | 99.99% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 50,158 |
| FTD / Avg. Volume | 2.71% |
Short Selling Information
The latest short interest is 10.64M, so 11.99% of the outstanding
shares have been sold short.
| Short Interest | 10.64M |
| Short % of Shares Out | 11.99% |
| Short % of Float | 13.25% |
| Short Ratio (days to cover) | 7.59 |
Valuation Ratios
The PE ratio is -4.27 and the forward
PE ratio is 23.82.
Travere Therapeutics's PEG ratio is
-0.02.
| PE Ratio | -4.27 |
| Forward PE | 23.82 |
| PS Ratio | 5.89 |
| Forward PS | 1.6 |
| PB Ratio | 23.26 |
| P/FCF Ratio | -4.06 |
| PEG Ratio | -0.02 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for Travere Therapeutics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.08,
with a Debt / Equity ratio of 6.8.
| Current Ratio | 2.08 |
| Quick Ratio | 2.04 |
| Debt / Equity | 6.8 |
| Debt / EBITDA | -1.51 |
| Debt / FCF | -1.19 |
| Interest Coverage | -28.67 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $605,649.35 |
| Profits Per Employee | $-835,181.82 |
| Employee Count | 385 |
| Asset Turnover | 0.39 |
| Inventory Turnover | 1.25 |
Taxes
| Income Tax | 120K |
| Effective Tax Rate | -0.04% |
Stock Price Statistics
The stock price has increased by 217.62% in the
last 52 weeks. The beta is 0.88, so Travere Therapeutics's
price volatility has been higher than the market average.
| Beta | 0.88 |
| 52-Week Price Change | 217.62% |
| 50-Day Moving Average | 18.42 |
| 200-Day Moving Average | 16.77 |
| Relative Strength Index (RSI) | 58.32 |
| Average Volume (20 Days) | 1,851,416 |
Income Statement
In the last 12 months, Travere Therapeutics had revenue of 233.18M
and earned -321.55M
in profits. Earnings per share was -4.08.
| Revenue | 233.18M |
| Gross Profit | 225.43M |
| Operating Income | -320.63M |
| Net Income | -321.55M |
| EBITDA | -265.77M |
| EBIT | -309.33M |
| Earnings Per Share (EPS) | -4.08 |
Full Income StatementBalance Sheet
The company has 58.53M in cash and 401.58M in
debt, giving a net cash position of -343.05M.
| Cash & Cash Equivalents | 58.53M |
| Total Debt | 401.58M |
| Net Cash | -343.05M |
| Retained Earnings | -1.45B |
| Total Assets | 548.8M |
| Working Capital | 191.71M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -237.47M
and capital expenditures -101.21M, giving a free cash flow of -338.69M.
| Operating Cash Flow | -237.47M |
| Capital Expenditures | -101.21M |
| Free Cash Flow | -338.69M |
| FCF Per Share | -4.29 |
Full Cash Flow StatementMargins
Gross margin is 96.68%, with operating and profit margins of -137.51% and -137.9%.
| Gross Margin | 96.68% |
| Operating Margin | -137.51% |
| Pretax Margin | -137.45% |
| Profit Margin | -137.9% |
| EBITDA Margin | -113.98% |
| EBIT Margin | -137.51% |
| FCF Margin | -145.25% |
